Key Points
- Sera Prognostics CEO Zhenya Lindgardt sold 28,215 shares on Dec. 9 at an average price of $3.04 for $85,773.60, leaving her with 768,081 shares — a 3.54% reduction in ownership.
- Shares traded down about 5.9% to $3.20 that day; the company reported Q3 EPS of ($0.16) (beating estimates) but only $0.02M in revenue and very negative margins and return on equity.
- Institutional investors own roughly 54.6% of the stock, yet analysts on aggregate maintain an average rating of "Sell".
Sera Prognostics, Inc. (NASDAQ:SERA - Get Free Report) CFO Austin Aerts sold 5,232 shares of Sera Prognostics stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $3.04, for a total value of $15,905.28. Following the completion of the transaction, the chief financial officer directly owned 273,087 shares of the company's stock, valued at approximately $830,184.48. This trade represents a 1.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link.
Austin Aerts also recently made the following trade(s):
- On Thursday, September 11th, Austin Aerts sold 915 shares of Sera Prognostics stock. The stock was sold at an average price of $3.13, for a total value of $2,863.95.
Sera Prognostics Trading Down 5.0%
SERA stock traded down $0.17 during mid-day trading on Thursday, reaching $3.23. The company's stock had a trading volume of 4,627 shares, compared to its average volume of 168,836. Sera Prognostics, Inc. has a 12 month low of $1.37 and a 12 month high of $9.13. The business's 50 day moving average price is $3.18 and its 200 day moving average price is $2.79. The company has a market cap of $124.66 million, a price-to-earnings ratio of -4.19 and a beta of 0.97.
Sera Prognostics (NASDAQ:SERA - Get Free Report) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.19) by $0.03. The company had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.10 million. Sera Prognostics had a negative net margin of 34,343.16% and a negative return on equity of 41.69%. As a group, equities analysts expect that Sera Prognostics, Inc. will post -0.96 EPS for the current fiscal year.
Analyst Ratings Changes
Several equities research analysts have weighed in on SERA shares. Wall Street Zen raised shares of Sera Prognostics from a "sell" rating to a "hold" rating in a research note on Saturday, October 25th. Weiss Ratings reissued a "sell (d-)" rating on shares of Sera Prognostics in a research note on Monday. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has a consensus rating of "Sell".
View Our Latest Stock Report on Sera Prognostics
Institutional Investors Weigh In On Sera Prognostics
A number of institutional investors and hedge funds have recently bought and sold shares of SERA. Squarepoint Ops LLC boosted its holdings in Sera Prognostics by 8.9% during the 3rd quarter. Squarepoint Ops LLC now owns 93,063 shares of the company's stock worth $285,000 after acquiring an additional 7,643 shares during the last quarter. XTX Topco Ltd bought a new position in shares of Sera Prognostics during the first quarter valued at about $39,000. Abel Hall LLC bought a new position in shares of Sera Prognostics during the second quarter valued at about $31,000. Wagner Wealth Management LLC purchased a new position in Sera Prognostics during the second quarter worth about $34,000. Finally, Citadel Advisors LLC grew its position in Sera Prognostics by 1.9% in the 3rd quarter. Citadel Advisors LLC now owns 653,746 shares of the company's stock worth $2,000,000 after purchasing an additional 12,439 shares in the last quarter. 54.64% of the stock is owned by hedge funds and other institutional investors.
About Sera Prognostics
(
Get Free Report)
Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
